Literature DB >> 8566841

Distribution of lactoferrin and 60/65 kDa heat shock protein in normal and inflamed human intestine and liver.

E Peen1, S Eneström, T Skogh.   

Abstract

Immunisation against the mycobacterial heat shock protein (hsp-65) has been proposed to lead to production of autoantibodies against human lactoferrin. Such antibodies occur in ulcerative colitis and in primary sclerosing cholangitis. This study analysed the distribution of hsp-65 and lactoferrin in biopsy specimens from patients with inflammatory bowel disease and primary sclerosing cholangitis and studied whether immunisation against mycobacterial hsp-65 resulted in production of antilactoferrin antibodies and vice versa. Polyclonal rabbit antihuman lactoferrin and monoclonal mouse anti-hsp-65 (ML30) were used for immunohistochemistry on biopsy specimens from patients with inflammatory bowel disease and primary sclerosing cholangitis. Rats were immunised against human lactoferrin and mycobacterial hsp-65 respectively. Antibody measurements were done by enzyme immunosorbent assays. It was found that lactoferrin and hsp-60/65 were not codistributed. Lactoferrin was found on vascular endothelium and in nonparenchymal liver cells both in inflamed and uninflamed tissues, but only in the hepatocytes of inflamed liver. ML30 reactivity was not inhibited by antilactoferrin antibodies. Rat anti-hsp-65 serum had no detectable antilactoferrin antibodies. In conclusion, antilactoferrin antibodies probably do not arise by immunisation against mycobacterial hsp-65. Both nonparenchymal cells and hepatocytes probably participate in clearance of lactoferrin. Endothelial exposure of lactoferrin may have pathogenic implications in diseases with antilactoferrin autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566841      PMCID: PMC1382992          DOI: 10.1136/gut.38.1.135

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Lactoferrin uptake by the rat liver. Characterization of the recognition site and effect of selective modification of arginine residues.

Authors:  G J Ziere; M C van Dijk; M K Bijsterbosch; T J van Berkel
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

2.  Cross-reactivity and sequence homology between the 65-kilodalton mycobacterial heat shock protein and human lactoferrin, transferrin, and DR beta subsets of major histocompatibility complex class II molecules.

Authors:  A Aguas; N Esaguy; C E Sunkel; M T Silva
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

3.  Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein.

Authors:  D Elias; D Markovits; T Reshef; R van der Zee; I R Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease.

Authors:  E Peen; S Almer; G Bodemar; B O Rydén; C Sjölin; K Tejle; T Skogh
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

5.  Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins.

Authors:  A Elsaghier; C Prantera; G Bothamley; E Wilkins; S Jindal; J Ivanyi
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 6.  Heat-shock proteins as immunogenic bacterial antigens with the potential to induce and regulate autoimmune arthritis.

Authors:  W van Eden
Journal:  Immunol Rev       Date:  1991-06       Impact factor: 12.988

7.  Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation.

Authors:  M S Cohen; J Mao; G T Rasmussen; J S Serody; B E Britigan
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

8.  Mycobacteria and human autoimmune disease: direct evidence of cross-reactivity between human lactoferrin and the 65-kilodalton protein of tubercle and leprosy bacilli.

Authors:  N Esaguy; A P Aguas; J D van Embden; M T Silva
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis.

Authors:  I E Coremans; E C Hagen; M R Daha; F J van der Woude; E A van der Voort; C Kleijburg-van der Keur; F C Breedveld
Journal:  Arthritis Rheum       Date:  1992-12

10.  Lactoferrin and lysozyme in the intrahepatic bile duct of normal livers and hepatolithiasis. An immunohistochemical study.

Authors:  K Saito; Y Nakanuma
Journal:  J Hepatol       Date:  1992-05       Impact factor: 25.083

View more
  3 in total

Review 1.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues.

Authors:  Leonie Beljaars; Hester I Bakker; Barry W A van der Strate; Catharina Smit; Adrian M Duijvestijn; Dirk K F Meijer; Grietje Molema
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

3.  Anti-lactoferrin antibodies and other types of anti-neutrophil cytoplasmic antibodies (ANCA) in reactive arthritis and ankylosing spondylitis.

Authors:  H Locht; T Skogh; E Kihlström
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.